Tremblay et al., 1990 - Google Patents
Complement receptor 2 mediates enhancement of human immunodeficiency virus 1 infection in Epstein-Barr virus-carrying B cells.Tremblay et al., 1990
View PDF- Document ID
- 3373636754398272677
- Author
- Tremblay M
- Meloche S
- Sekaly R
- Wainberg M
- Publication year
- Publication venue
- Journal of Experimental Medicine
External Links
Snippet
The human immunodeficiency virus (HIV) has a marked tropism for human T lymphocytes expressing the CD4 glycoprotein. This molecule has been identified as the major cellular receptor for the HIV envelope protein gp120 (reviewed in reference 1). However, several …
- 241000713772 Human immunodeficiency virus 1 0 title abstract description 36
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tremblay et al. | Complement receptor 2 mediates enhancement of human immunodeficiency virus 1 infection in Epstein-Barr virus-carrying B cells. | |
| Thali et al. | Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody | |
| Clapham et al. | Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells | |
| Homsy et al. | Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals | |
| AU613382B2 (en) | Method of selectively inhibiting hiv | |
| Stein et al. | pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane | |
| Ahmad et al. | Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection | |
| Mascola et al. | Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12 | |
| Teitz et al. | Inhibition of human immunodeficiency virus by N-methylisatin-β4′: 4′-diethylthiosemicarbazone and N-allylisatin-β-4′: 4′-diallythiosemicarbazone | |
| Luzuriaga et al. | HIV-1-specific cytotoxic T lymphocyte responses in the first year of life. | |
| Tremblay et al. | Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera | |
| Chehimi et al. | In vitro infection of natural killer cells with different human immunodeficiency virus type 1 isolates | |
| Perno et al. | Infection of monocytes by human immunodeficiency virus type 1 blocked by inhibitors of CD4-gp120 binding, even in the presence of enhancing antibodies. | |
| Ikuta et al. | Expression of human immunodeficiency virus type 1 (HIV-1) gag antigens on the surface of a cell line persistently infected with HIV-1 that highly expresses HIV-1 antigens | |
| Schmitz et al. | Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59. | |
| Montefiori et al. | V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network. | |
| PLATA et al. | HIV-1 infection of lung alveolar fibroblasts and macrophages in humans | |
| Salahuddin et al. | HTLV‐III infection of EBV‐genome‐positive B‐lymphoid cells with or without detectable T4 antigens | |
| Burkly et al. | Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies | |
| Schmitt et al. | Permissivity of primary cultures of human Kupffer cells for HIV-1 | |
| Cheng-Mayer et al. | Altered host range of HIV-1 after passage through various human cell types | |
| Sullivan et al. | Complement can neutralize HIV-1 plasma virus by a C5-independent mechanism | |
| Hoxie et al. | Cytopathic variants of an attenuated isolate of human immunodeficiency virus type 2 exhibit increased affinity for CD4 | |
| Torpey III et al. | Effects of adoptive immunotherapy with autologous CD8+ T lymphocytes on immunologic parameters: lymphocyte subsets and cytotoxic activity | |
| McKeating et al. | Recombinant CD4-selected human immunodeficiency virus type 1 variants with reduced gp120 affinity for CD4 and increased cell fusion capacity |